lapatinib has been researched along with transforming growth factor beta in 6 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (transforming growth factor beta) | Trials (transforming growth factor beta) | Recent Studies (post-2010) (transforming growth factor beta) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 49,119 | 560 | 17,610 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Crane, K | 1 |
| Bassano, C; Centritto, F; Flora, M; Fratelli, M; Garattini, E; Gardini, G; Guarnaccia, V; Paroni, G; Terao, M; Ubezio, P; Zanetti, A | 1 |
| Andrianifahanana, M; Becker, J; Edens, M; Gupta, SK; Leof, EB; Maidl, E; Rahimi, RA; Repellin, CE; Wilkes, MC; Wittenberger, J; Yin, X | 1 |
| Cheng, M; Conteh, AM; Craven, KE; Gore, J; Imasuen-Williams, IE; Korc, M | 1 |
| Akhand, SS; Brown, WS; Wendt, MK | 1 |
| Boswell, BA; Musil, LS; VanSlyke, JK | 1 |
6 other study(ies) available for lapatinib and transforming growth factor beta
| Article | Year |
|---|---|
Elucidating an uncommon disease: inflammatory breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diagnosis, Differential; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Mastitis; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Quinazolines; Receptor, ErbB-2; Remission Induction; Taxoids; Transforming Growth Factor beta; Trastuzumab; Treatment Outcome | 2011 |
Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Amplification; Humans; Lapatinib; Phosphorylation; Quinazolines; Receptor, ErbB-2; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Smad3 Protein; Transcription, Genetic; Transcriptome; Transforming Growth Factor beta; Tretinoin | 2012 |
Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases.
Topics: Animals; Benzamides; Bleomycin; Cell Line; Drug Interactions; Epidermal Growth Factor; ErbB Receptors; Feedback, Physiological; Imatinib Mesylate; Lapatinib; Lung; Mice; Myofibroblasts; Paracrine Communication; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pulmonary Gas Exchange; Pyrimidines; Quinazolines; Receptor, ErbB-2; Receptors, Platelet-Derived Growth Factor; Transforming Growth Factor beta; Up-Regulation | 2013 |
Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Movement; Cyclin-Dependent Kinase Inhibitor p16; ErbB Receptors; Female; Gene Expression Profiling; Genes, Retinoblastoma; Genetic Predisposition to Disease; Humans; Lapatinib; Lymphangiogenesis; Male; Mice, Transgenic; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Neovascularization, Pathologic; Pancreatic Neoplasms; Phenotype; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyrazoles; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta | 2016 |
FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Fibroblast Growth Factor 2; Humans; Hyaluronan Receptors; Lapatinib; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nuclear Proteins; Phenotype; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Time Factors; Transforming Growth Factor beta; Twist-Related Protein 1; Xenograft Model Antitumor Assays | 2016 |
ErbBs in Lens Cell Fibrosis and Secondary Cataract.
Topics: Capsule Opacification; Cataract; Epithelial Cells; Fibrosis; Humans; Lapatinib; Ligands; Transforming Growth Factor beta | 2023 |